Morning Trend | Synlogic dominated by short interest, can it wait for a counterattack under pressure?
Synlogic (SYBX.US) continued to fight the bottom line this week, with the bulls basically giving up resistance and a bearish atmosphere dominating the market—on November 28th, it hit a new low again, and the community is filled with lamentations, with a prevailing wait-and-see sentiment. The most concerning aspect is the negative feedback from the news: delays in the approval of its main product have affected sentiment, and funds are unwilling to bet on the bottom in advance. Recently, in the small-cap biopharmaceutical sector, whoever rebounds gets hit hard, and the entire sector has turned into a "risk-averse zone." Technical analysts point out that the system moving averages are repeatedly pressing down, and any occasional rebound on the intraday chart is merely a self-rescue from overselling, with no following funds. More people in the community are watching to see if "a big bullish reversal can emerge"—but given the current weakness, any intraday fluctuations can easily be crushed by the main force, and positions need to be tightly controlled, with stop-losses set to follow intraday signals. Unexpectedly negative news can amplify volatility at any time, and "breaking the bottom at any moment, soft yet firm" is the current description. Operational advice: Signals for bottom rebounds must be decisively acted upon to secure early profits, while conservative players are advised to stay in cash and wait for confirmation of intraday fluctuations. Maintain the right mindset; although there are opportunities under high pressure, the risks are greater, with a focus on volume fluctuations and the effects of news
Synlogic (SYBX.US) continued to fight the bottom line this week, with the bulls basically giving up resistance and a bearish atmosphere dominating the market—on November 28th, it hit a new low again, and the community is filled with lamentations, with a prevailing wait-and-see sentiment.
The most concerning aspect is the negative feedback from the news: delays in the approval of its main product have affected sentiment, and funds are unwilling to bet on the bottom in advance. Recently, in the small-cap biopharmaceutical sector, any rebound is met with selling, and the entire sector has turned into a "risk-averse zone." Technical analysts point out that the system moving averages are repeatedly pressing down, and any occasional rebound on the intraday chart is merely a self-rescue from overselling, with no following funds.
More people in the community are watching to see if there can be a "big bullish counterattack"—but given the current weakness, any intraday fluctuations can easily be crushed by the main force, and positions need to be strictly controlled, with stop-losses set to follow intraday signals. Unexpectedly negative news can amplify volatility at any time, and "breaking the bottom at any moment, soft yet firm" is the current description.
Operational advice: Signals for bottom rebounds must be decisively entered for early profit-taking; for those who prefer a cautious approach, it is best to stay in cash and wait for confirmation of intraday fluctuations. Maintain the right mindset; although there are opportunities under high pressure, the risks are greater, with a focus on volume fluctuations and the effects of news
